

**KLK14 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6333b****Specification**

---

**KLK14 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q9P0G3](#)**KLK14 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 43847**Other Names**

Kallikrein-14, hK14, 3421-, Kallikrein-like protein 6, KLK-L6, KLK14, KLKL6

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6333b](/product/products/AP6333b) was selected from the C-term region of human KLK14. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**KLK14 Antibody (C-term) Blocking Peptide - Protein Information****Name** KLK14**Synonyms** KLKL6**Function**

Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression including growth, invasion and angiogenesis.

**Cellular Location**

Secreted, extracellular space

**Tissue Location**

Highly expressed in CNS, bone marrow and fetal liver. Also expressed in breast, thyroid, kidney, colon, pancreas, spleen, prostate, uterus, small intestine, placenta and skeletal muscle. Among 40 tissues tested, the highest expression is detected in skin followed by breast and prostate (at protein level). Expressed in stratum corneum by sweat ducts and sweat glands and detected in sweat (at protein level).

**KLK14 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**KLK14 Antibody (C-term) Blocking Peptide - Images****KLK14 Antibody (C-term) Blocking Peptide - Background**

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK14 is expressed by both benign and malignant glandular epithelial cells, thus exhibiting an expression pattern similar to that of two other prostatic kalikreins, KLK2 and KLK3.

**KLK14 Antibody (C-term) Blocking Peptide - References**

Brattsand, M., et al., J. Invest. Dermatol. 124(1):198-203 (2005).Yousef, G.M., et al., Prostate 56(4):287-292 (2003).Yousef, G.M., et al., Br. J. Cancer 87(11):1287-1293 (2002).Hooper, J.D., et al., Genomics 73(1):117-122 (2001).Yousef, G.M., et al., Cancer Res. 61(8):3425-3431 (2001).